Suven Pharmaceuticals Limited

BSE: 543064
Suven Pharmaceuticals Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U24299TG2018PLC128171 Incorporated 06 November 2018 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - BSE: 543064 Public Limited Company pharma
Data last updated
Revenue · FY 2022
₹1,508.01 Cr
▲ 47% YoY
Net profit · FY 2022
₹558.1 Cr
Net margin 37%
EBITDA · FY 2022
₹703.18 Cr
EBITDA margin 46.6%
Authorised capital
₹40 Cr
Registered with MCA
Paid-up capital
₹25.46 Cr
Issued & subscribed
Open charges
₹174.02 Cr
Secured borrowings
Company age
8 yrs
Est. 2018
Employees · EPFO
943
Provident fund records

About Suven Pharmaceuticals Limited

Data last updated:

Suven Pharmaceuticals Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Jasti Property And Equity Holdings Private Limited. It operates in the pharmaceutical formulations segment of the pharmaceuticals sector. It was incorporated on 06 November 2018 and has been in existence for over 8 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24299TG2018PLC128171. Its GSTIN is 36ABBCS1159F1ZI (Telangana). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 543064.

The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹25.46 Cr. It is led by director Jerry Jeyasingh.

Its last annual general meeting (AGM) was held on 31 August 2021, and its latest financial statements are for the year ended 31 March 2021. The registered office is at Hyderabad, Telangana.

As per the financials filed for FY 2022, the company reported a revenue of ₹1,508.01 Cr, a growth of 47% compared to the previous year. For the same year it recorded a net profit of ₹558.1 Cr (net margin 37%) and EBITDA of ₹703.18 Cr (EBITDA margin 46.6%). Revenue has grown at a compounded annual rate (CAGR) of 59% over three years.

The company has about 943 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Suven Pharma. As per MCA filings, the company has open charges of ₹174.02 Cr on record. Court records list 18 cases involving the company, including 8 filed by the company and 10 filed against it; 6 cases are pending.

For more details, the company can be reached via its website suvenpharm.com.

Company details

CIN U24299TG2018PLC128171
Registration Number 128171
Incorporation Date 06 November 2018
ROC Hyderabad
Listing Status Listed - Listed on BSE (543064)
Company Status Active
Date of Last AGM 31 August 2021
Date of Balance Sheet 31 March 2021
Parent Company Jasti Property And Equity Holdings Private Limited

CIN history

Suven Pharmaceuticals has one previous CIN (Corporate Identification Number): L24299TG2018PLC128171. The current CIN is U24299TG2018PLC128171, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24299TG2018PLC128171Current
L24299TG2018PLC128171Previous
Key People
Jerry Jeyasingh Director

Recognitions & Rankings of Suven Pharmaceuticals

India's Most Valuable Companies 2023 edition · Source: Hurun India
Rank#274
Valuation
₹14,361 Cr
2022 #327 2021 #268

Contact details

Suven Pharmaceuticals Limited's registered office is in Hyderabad, Telangana. Its website is suvenpharm.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    suvenpharm.com
  • Registered Address
    # 8 – 2 – 334 Sde Serene Chambers 3rd Floor, Avenue 7 Road No. 5 Banjara Hills, Hyderabad, Telangana, India – 500034
  • Industry
    Pharma, Pharmaceutical Formulations

To see the full contact details of Suven Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Suven Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Suven Pharmaceuticals operates one associated brand: Suven Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Suven Pharma
Contract manufacturing and development of APIs and formulations are provided.suvenpharm.com

Financials of Suven Pharmaceuticals Limited

FY 2021 filings available

Suven Pharmaceuticals Limited reported revenue of ₹1,508.01 Cr (up 47% YoY) for FY 2022.

Revenue · FY 2022
₹1,508.01 Cr ▲ 47%
Net profit · FY 2022
₹558.1 Cr margin 37%
EBITDA · FY 2022
₹703.18 Cr margin 46.6%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 47%
3 years · compounded
▲ 59%
EBITDA CAGR growth
1 year
▲ 60%
3 years · compounded
▲ 60%

Revenue has grown at a compounded annual rate (CAGR) of 59% over three years, including 47% growth in the latest year. EBITDA rose 60% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹1,508.01 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹703.18 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹558.1 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profitability
EBITDA Margin46.6%
Net Profit Margin37%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Suven Pharmaceuticals Limited, buy the company report.

Board of directors of Suven Pharmaceuticals Limited

Suven Pharmaceuticals has 1 current director and 1 former director. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Jerry JeyasinghDirector06 Nov 20196 Years 11 MonthsCurrent
View all directors

Auditor

Suven Pharmaceuticals Limited is audited by KARVY & CO for the financial year 2021.

Auditor firmFinancial yearFirm registration number
KARVY & COFY 2021001757S

Shareholding

The shareholding of Suven Pharmaceuticals Limited is on record for 2 financial years, the latest being FY 2021, split between promoters, domestic institutions, public shareholders and others.

Shareholder categoryFY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Public
Others

To see the full shareholding pattern of Suven Pharmaceuticals Limited, buy the company report.

Charges & borrowings

Open charges
₹174.02 Cr
Satisfied charges
None
Breakdown by lending institutions
State Bank of India₹164.02 Cr
Bank of Bahrain and Kuwait Bsc₹10.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
29 Dec 2020100402459Bank of Bahrain and Kuwait Bsc₹10 CrOpen
05 Nov 2020100391471State Bank of India₹164.02 CrOpen

To see the full charge records of Suven Pharmaceuticals Limited, buy the company report.

Total charge records: 2 View all charges

Credit ratings & regulatory alerts

Suven Pharmaceuticals Limited was last rated by Crisil on 23 Apr 2020.

Rating agencyRated onRating
Crisil23 Apr 2020

To see the full credit ratings and regulatory alerts of Suven Pharmaceuticals Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Suven Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Suven Pharmaceuticals Limited has a workforce of 877 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.

Employee count
877
Active EPFO establishments
1
Employee growth
-6.8%

GST

Suven Pharmaceuticals has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
36ABBCS1159F1ZITelanganaActive14 Oct 2019
37ABBCS1159F1ZGAndhra PradeshActive31 Dec 2019

To see the full GST registrations and return filing status of Suven Pharmaceuticals Limited, buy the company report.

Recent activity

Suven Pharmaceuticals Limited has 1 board change on record since 2019: 1 appointment. The latest: Jerry Jeyasingh was appointed as Director on 06 Nov 2019.

AGM
Suven Pharmaceuticals Limited last Annual general meeting of members was held on 31 Aug 2021 as per latest MCA records.
Filing
Suven Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2021 with RoC-Hyderabad.
Charges
A charge with Bank Of Bahrain And Kuwait Bsc amounted to Rs. 10.00 Cr with Charge ID 100402459 was registered on 29 Dec 2020.
Charges
A charge with State Bank Of India of Rs. 164.02 Cr registered on 05 Nov 2020 with Charge ID 100391471 was modified on 28 Dec 2020.
Charges
A charge with State Bank Of India amounted to Rs. 164.02 Cr with Charge ID 100391471 was registered on 05 Nov 2020.
Appointed
Jerry Jeyasingh was appointed as Director.
Incorporation
06 Nov 2018
Suven Pharmaceuticals Limited was registered on 06 Nov 2018 with RoC-Hyderabad & aged 7 years 11 months as per MCA records.

News

Cohance Lifesciences: Names Mr. Abhimanyu Ojha As CFO Starting October 12, 2026, With Over 20 Years Of Finance Experience In Global Healthcare And Pharmaceuticals; Formerly Global CFO At Intas Pharmaceuticals.
09 Oct 2026 · Exchange Update
Cohance Lifesciences: Jaggaiahpet API Facility Passes USFDA Inspection With Five Noted Observations.
21 Sep 2026 · Exchange Update

Frequently asked questions

Suven Pharmaceuticals is an active public limited company based in Hyderabad, Telangana, India. The company works in pharmaceutical formulations, within the pharma industry. It was incorporated on 06 November 2018 (8+ years old) and is registered under CIN U24299TG2018PLC128171. Listed on BSE: 543064.

Suven Pharmaceuticals has 1 current director:

The latest financial statements of Suven Pharmaceuticals on record with the MCA are for the year ended 31 March 2021. Its last annual general meeting was held on 31 August 2021. Year-wise statements from FY 2019 are in the company report.

The GSTIN of Suven Pharmaceuticals is 36ABBCS1159F1ZI, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 37ABBCS1159F1ZG (Andhra Pradesh).

The CIN (Corporate Identification Number) of Suven Pharmaceuticals is U24299TG2018PLC128171. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Suven Pharmaceuticals is a listed company as per MCA records. Its shares are listed on BSE (code: 543064).

Suven Pharmaceuticals has 18 court cases on record: 8 filed by the company and 10 filed against it. 6 are pending. Most are in the high courts.

Suven Pharmaceuticals was incorporated on 06 November 2018, making it 8+ years old. It is registered with the Registrar of Companies, Hyderabad.

Jerry Jeyasingh was appointed as Director on 06 Nov 2019.

Suven Pharmaceuticals can be reached through the website suvenpharm.com. Its registered office is in Hyderabad, Telangana, India.